Nifedipine
- Generic Name
- Nifedipine
- Brand Names
- Adalat, Afeditab CR, Nifediac, Nifedical, Procardia
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N2O6
- CAS Number
- 21829-25-4
- Unique Ingredient Identifier
- I9ZF7L6G2L
- Background
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is amlodipine.
Nifedipine was granted FDA approval on 31 December 1981.
- Indication
Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.
- Associated Conditions
- Achalasia, Chronic Stable Angina Pectoris, Fissure;Anal, Hypertension, Hypertensive Emergency, Premature Labour, Proctalgia, Pulmonary Edemas, Pulmonary Hypertension (PH), Raynaud's Phenomenon, Ureteral Calculus, Vasospastic Angina
PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy
- Conditions
- Postpartum Hypertension (PPHT)
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 110
- Registration Number
- NCT06915792
Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine
- Conditions
- Severe Preeclampsia
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 60
- Registration Number
- NCT06265415
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 618
- Registration Number
- NCT06220721
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Treatment of Elevated Blood Pressures in Early Pregnancy
- Conditions
- Elevated Blood PressurePregnancy Induced Hypertension
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Marshall University
- Target Recruit Count
- 2
- Registration Number
- NCT05955040
- Locations
- 🇺🇸
Marshall Obstetrics and Gynecology, Huntington, West Virginia, United States
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Hasten Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 1215
- Registration Number
- NCT05947448
- Locations
- 🇨🇳
Junbo Ge, Shanghai, Shanghai, China
Medicine-induced Cardiac Hemodialysis on COVID-19
- Conditions
- Severe Acute Respiratory Syndrome-related CoronavirusRenal DialysisMyocarditis AllergicVaccinesInfection Viral
- Interventions
- Diagnostic Test: Kangzhu BPCB0A-3ABehavioral: Low MobilityDietary Supplement: Coenzyme Q10Dietary Supplement: d-alpha tocopherol acetateDietary Supplement: Omega-3
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Yang I. Pachankis
- Target Recruit Count
- 1
- Registration Number
- NCT05711810
- Locations
- 🇨🇳
Residential Address, Chongqing, Chongqing, China
Intensive Postpartum Antihypertensive Treatment
- Conditions
- Hypertensive Disorder of Pregnancy
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 60
- Registration Number
- NCT05687344
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism
- Conditions
- Primary AldosteronismEndocrine Hypertension
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 15
- Registration Number
- NCT05686993
- Locations
- 🇬🇧
St Bartholomew's Hospital, London, United Kingdom
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
- Conditions
- Postpartum ComplicationMaternal HypertensionHigh Blood Pressure
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Loma Linda University
- Target Recruit Count
- 500
- Registration Number
- NCT05551104
- Locations
- 🇺🇸
Loma Linda University Health, Loma Linda, California, United States
The Treatment of Magnesium Sulfate and Nifedipine in Preterm Labor Threat
- Conditions
- Preterm Labor Without DeliveryPregnancy Preterm
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Konya Meram State Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05520021
- Locations
- 🇹🇷
Hasan Ali Inal, Antalya, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.